Feb 24, 2026 04:05PM
Feb 17, 2026 08:30AM
Feb 9, 2026 11:15AM
Feb 9, 2026 11:14AM
Dec 22, 2025 07:06AM
Dec 9, 2025 07:00AM
Oct 24, 2025 08:29AM Piper Sandler: 'Biotech Has a Heartbeat: 17 Stocks to Own Through YE25'
Sep 17, 2025 04:30PM
Sep 17, 2025 04:30PM
Jul 31, 2025 08:44AM
Jul 31, 2025 08:44AM
Jun 17, 2025 06:42AM
Jun 16, 2025 07:01AM
Jun 16, 2025 07:00AM Supernus Pharmaceuticals to Acquire Sage Therapeutics, Strengthening its Neuropsychiatry Product Portfolio
May 29, 2025 08:30AM
May 28, 2025 04:05PM
May 20, 2025 08:30AM
Feb 25, 2025 04:01PM
Feb 4, 2025 11:28AM
Feb 4, 2025 11:19AM
Feb 4, 2025 09:02AM Supernus Pharma (SUPN) Announces FDA Approval of ONAPGO for Parkinson’s Disease
Feb 4, 2025 09:00AM
Jan 27, 2025 08:00AM
Jan 27, 2025 08:00AM
Jan 27, 2025 08:00AM
Nov 4, 2024 04:05PM
Sep 24, 2024 07:30AM
Aug 19, 2024 07:01AM Supernus Pharma (SUPN) Announces SPN-830 Apomorphine Infusion Device NDA Accepted for Review by FDA
Aug 19, 2024 07:00AM
Aug 1, 2024 04:30PM
May 23, 2024 04:06PM
May 23, 2024 04:05PM
May 8, 2024 04:05PM
May 7, 2024 10:01AM
May 7, 2024 10:00AM M8 Pharmaceuticals, an Acino company, signs an exclusive licensing agreement with Supernus for Qelbree® (Viloxazine XR) in Latin America
Apr 8, 2024 10:10AM
Apr 8, 2024 10:09AM
Apr 8, 2024 08:05AM
Apr 8, 2024 08:00AM
Feb 27, 2024 04:05PM
Feb 5, 2024 08:31AM
Feb 5, 2024 08:30AM Supernus Wins Infringement and Validity Case on Trokendi XR® against Torrent
Nov 8, 2023 04:05PM
Nov 2, 2023 07:06AM
Nov 2, 2023 07:00AM
Oct 16, 2023 05:34PM
Oct 9, 2023 04:45PM
Oct 9, 2023 04:45PM
Sep 10, 2023 05:17AM Supernus Pharma (SUPN) Reports New Qelbree Data Showing Improvement in ADHD Symptoms
Sep 9, 2023 08:00PM

312,667 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All